1. Scrip
  2. >>Business
  3. >>Deals

A Grunenthal First: Establishing A US Presence With A Tailored Marketing Strategy

 
• By John Davis

Germany's pain-focused specialty pharmaceutical firm is adding America to its commercial reach, through acquiring New York's Averitas Pharma to jumpstart its push to commercialize products on its own account, via a niche approach.  

Broken arm
Complex regional pain syndromes often involve injured extremities. • Source: Shutterstock

By acquiring the small New York-based company, Averitas Pharma, the family-owned European-based specialty company, Grunenthal GMBH, is aiming to use Averitas's experience in a specialty pharmacy and hub services model to commercialize, for the first time, its own portfolio of niche pain-related therapies in the US.

The acquisition confirms that US market opportunities are as much a draw for privately held companies as they are for publicly quoted companies. Another mid-sized European pharmaceutical company, the Nasdaq...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

 
• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

Stock Watch: Q1 Sales Trends And Forex Muddle Pharma Outlook

 
• By Andy Smith

Pharma firms tended to downplay first-quarter trends in full-year guidance. However, raised guidance seems fragile amid ongoing foreign exchange effects and Medicare Part D redesign pressures.